newsfilter
← Latest News
Business Wire·

Dicerna Announces Boehringer Ingelheim's Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement

Development Candidate Will Be Evaluated for Treatment of Nonalcoholic Steatohepatitis Candidate Selection Triggers Single-Digit Multimillion USD Milestone Payment to Dicerna Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) (the "Company" or "Dicerna"),